RE: “Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer,” by Ding H., et al.

Claire Telford

doi:10.1111/ecc.12834

RE: “Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer,” by Ding H., et al.

European Journal of Cancer Care ◽

10.1111/ecc.12834 ◽

2018 ◽

Vol 27 (2) ◽

pp. e12834

Author(s):

Claire Telford

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer

European Journal of Cancer Care ◽

10.1111/ecc.12733 ◽

2017 ◽

Vol 26 (6) ◽

pp. e12733 ◽

Cited By ~ 10

Author(s):

H. Ding ◽

L. Fang ◽

W. Xin ◽

Y. Tong ◽

Q. Zhou ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

First-line Treatment with Ribociclib plus Endocrine Therapy for Premenopausal Women with Hormone-receptor-positive Advanced Breast Cancer: A Cost-effectiveness Analysis

Clinical Breast Cancer ◽

10.1016/j.clbc.2021.01.019 ◽

2021 ◽

Author(s):

Xiaoting Huang ◽

Shen Lin ◽

Xin Rao ◽

Dayong Zeng ◽

Hang Wang ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Premenopausal Women ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Comparative Efficacy of CDK4/6 Inhibitors Plus Aromatase Inhibitors Versus Fulvestrant for the First-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer: A Network Meta-Analysis

Targeted Oncology ◽

10.1007/s11523-019-00633-9 ◽

2019 ◽

Vol 14 (2) ◽

pp. 139-148 ◽

Cited By ~ 5

Author(s):

Qianqian Guo ◽

Xiaojie Lin ◽

Lingling Ye ◽

Rui Xu ◽

Yan Dai ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Meta Analysis ◽

Line Treatment ◽

Comparative Efficacy ◽

First Line ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

Breast Cancer ◽

10.1007/s12282-019-01034-6 ◽

2019 ◽

Vol 27 (3) ◽

pp. 399-404 ◽

Cited By ~ 1

Author(s):

Weiting Liao ◽

Jiaxing Huang ◽

Qiuji Wu ◽

Feng Wen ◽

Nan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Metastatic Breast ◽

Cost Effectiveness Analysis ◽

First Line ◽

Hormone Receptor Positive ◽

Effectiveness Analysis

Download Full-text

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2495-0 ◽

2013 ◽

Vol 138 (3) ◽

pp. 961-965 ◽

Cited By ~ 13

Author(s):

Pui San Tan ◽

Benjamin Haaland ◽

Alberto J. Montero ◽

Gilberto Lopes

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Meta Analysis ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK

PharmacoEconomics - Open ◽

10.1007/s41669-019-0134-3 ◽

2019 ◽

Vol 3 (4) ◽

pp. 559-570 ◽

Cited By ~ 2

Author(s):

Claire Telford ◽

Evelina Bertranou ◽

Samuel Large ◽

Hilary Phelps ◽

Mattias Ekman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

The Uk

Download Full-text

P1-16-01: A Randomized, Double-Blinded, Controlled Study of Exemestane vs. Anastrozole for the First-Line Treatment of Postmenopausal Japanese Women with Hormone Receptor Positive Advanced Breast Cancer.

10.1158/0008-5472.sabcs11-p1-16-01 ◽

2011 ◽

Author(s):

N Masuda ◽

H Iwata ◽

S Ohno ◽

Y Rai ◽

Y Sato ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Japanese Women ◽

Controlled Study ◽

Line Treatment ◽

First Line ◽

Hormone Receptor Positive ◽

Double Blinded ◽

First Line Treatment

Download Full-text

Cyclin-dependent kinase inhibitors plus aromatase inhibitor in first-line treatment hormone-receptor–positive/HER2-negative advanced breast cancer women with or without visceral disease

Anti-Cancer Drugs ◽

10.1097/cad.0000000000000904 ◽

2020 ◽

Vol 31 (5) ◽

pp. 528-532

Author(s):

Olga Nigro ◽

Cristina Marrazzo ◽

Elisa Gallerani ◽

Linda Bascialla ◽

Rossana Gueli ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Kinase Inhibitors ◽

Line Treatment ◽

Cyclin Dependent Kinase ◽

First Line ◽

Hormone Receptor Positive ◽

Visceral Disease ◽

First Line Treatment

Download Full-text

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2573-3 ◽

2013 ◽

Vol 139 (2) ◽

pp. 441-451 ◽

Cited By ~ 21

Author(s):

Hiroji Iwata ◽

Norikazu Masuda ◽

Shinji Ohno ◽

Yoshiaki Rai ◽

Yasuyuki Sato ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Japanese Women ◽

Controlled Study ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Hormone Receptor Positive ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as frist-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): A UK perspective

European Journal of Cancer ◽

10.1016/s0959-8049(02)80202-7 ◽

2002 ◽

Vol 38 (11) ◽

pp. S68

Author(s):

R Simons

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Cost Effectiveness Analysis ◽

Advanced Breast ◽

Hormone Receptor Positive ◽

Effectiveness Analysis ◽

Line Therapy

Download Full-text